FindTrial
Sign In

Immunohematogical markers in Graves disease

Assessment of Immunohematological Biomarkers in the diagnosis of Graves� disease and in monitoring the response to medical treatment.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/12/038899
Enrollment
100
Registered
2021-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E050- Thyrotoxicosis with diffuse goiter

Interventions

None listed

Sponsors

Jayanthy Ramesh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Any new patient with thyrotoxicosis

Exclusion criteria

Exclusion criteria: Those who refuse consent

Design outcomes

Primary

MeasureTime frame
No of Patients diagnosed with graves vs toxic nodules vs toxic MNG vs hashimotos thyroiditisTimepoint: No of Patients diagnosed with graves vs toxic nodules vs toxic MNG vs hashimotos thyroiditis—

Secondary

MeasureTime frame
Follow up of Gravesââ?¬â?¢ disease patientsTimepoint: 6 months—

Countries

India

Contacts

Public ContactJayanthy Ramesh

Andhra Medical College

drjayanthyramesh@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026